Compare Regeneron Pharmaceuticals Inc (REGN) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Direxion Daily S&P 500 Bull 3X Shares trades at $267.85. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | SPXL | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $812.27 | $288.04 |
52-Week Low | $545.46 | $170.20 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SPXL is trading at $264.57, down 0.44% with a bearish technical signal. The ETF faces resistance at the 50-day moving average while support levels cluster around $262-$254. Recent news highlights S&P 500 valuation concerns with Shiller CAPE ratios approaching historic highs, creating headwinds for leveraged index products.
The leveraged ETF's performance remains tied to S&P 500 momentum amid mixed earnings sentiment. Key risks include market concentration in tech stocks and potential AI bubble concerns, while institutional analysis suggests the broader market may still deliver double-digit gains through 2026 despite valuation pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
